Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 for the $8.2 Billion Market

Prostate Cancer - Global Drug Forecast and
Market Analysis to 2023 for the $8.2 Billion
Market
"PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023" report to their
offering. Prostate Cancer Treatment Market Value Will Treble to $8.2 Billion by 2023 The global
treatment market value for prostate cancer, excluding hormonal and bone therapies, will expand more
than threefold from $2.6 billion in 2013 to an estimated $8.2 Billion.
This report, "PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023" focuses
on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate
cancer.
Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Prostate Cancer - Global
Drug Forecast and Market Analysis Report at – http://www.absolutereports.com/pharmapointprostate-cancer-global-drug-forecast-and-market-analysis-to-2023-10076081
Scope of The Prostate Cancer - Global Drug Forecast and Market Analysis Report:
- Overview of prostate cancer, including epidemiology, etiology, pathophysiology, clinical staging,
symptoms, prognosis, quality of life, and disease management.
- Annualized prostate cancer therapeutics market revenue from 2013-2023. Annual cost of therapy, and
major marketed and pipeline drug sales in this forecast period are included.
Ask for Discount on Prostate Cancer - Global Drug Forecast and Market Analysis Report at –
http://www.absolutereports.com/enquiry/request-discount/10076081
Key Questions Answered in This Report:
- How will prostate cancer disease management change as new agents enter the market?
- Which prostate cancer patients have the greatest unmet needs and how well will these needs be
addressed by the new agents?
- What are the most dominant players in the prostate cancer space and what corporate strategies are
+1 408 520 9750
www.absolutereports.com
pursued by these companies?
- What are the most promising late-stage pipeline agents for prostate cancer? How do they compare to
currently marketed products?
- What opportunities will remain for future players following the launch of these pipeline agents?
Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10076081
The key findings of the reports is that the prostate cancer pipeline is robust with nine drugs in late-stage
development. While androgen biosynthesis is still a major target, many of the pipeline candidates have
diverse mechanisms of action and target proteins and pathways that are not targeted by the currently
marketed prostate cancer treatments. Among these new candidates are a checkpoint inhibitor, a
clusterin inhibitor, and an anti-angiogenic agent. There are also several vaccines, both autologous and
off-the-shelf, that have a significant presence in this pipeline.
About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business
world in strategizing and taking visionary decisions based on facts and figures derived from in depth
market research. We are one of the top report resellers in the market, dedicated towards bringing you
an ingenious concoction of data parameters.
Contact–
Mr. Ameya Pingaley
Absolute Reports
+1-408 520 9750
Email – sales@absolutereports.com
Website: www.absolutereports.com
+1 408 520 9750
www.absolutereports.com